FDA advisory committee considers two LDL-lowering drugs this week
An FDA advisory panel is considering two drugs that lower low-density lipoprotein cholesterol, the Wall Street Journal reports. The injectable medications (evolocumab and alirocumab) are proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and are expected to be used in patients who cannot tolerate statins or who failed with previous statin therapy.
Executive Editor
Tim Casey joined TriMed Media Group in 2015 as Executive Editor. For the previous four years, he worked as an editor and writer for HMP Communications, primarily focused on covering managed care issues and reporting from medical and health care conferences. He was also a staff reporter at the Sacramento Bee for more than four years covering professional, college and high school sports. He earned his undergraduate degree in psychology from the University of Notre Dame and his MBA degree from Georgetown University.